Gene expression variance based on random sequencing in rat remnant kidney. *Naoshi Horiba, Satohiro Masuda, Ayako Takeuchi, Hideyuki Saito, Masahiro Okuda, and Ken-ichi Inui* 29

Homozygosity for uromodulin disorders: FJHN and MCKD-type 2. *Wânia Rezende-Lima, Kleber S. Parreira, Miguel García-González, Eva Riveira, Julio F. Banet, and Xosé M. Lens* 558

Prevalence of *WT1* mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome. *Rainer G. Ruf, Michael Schultheiss, Anne Lichtenberger, Stephanie M. Karle, Isabella Zalewski, Bettina Mucha, Anne Schulze Everding, Thomas Neuhaus, Ludwig Patzer, Christian Plank, Johannes P. Haas, Fatih Ozaltin, Anita Imm, Arno Fuchshuber, Aysin Bakkaloglu, Friedhelm Hildebrandt, and Members of the APN Study Group* 564

NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. *Stefanie Weber, Olivier Gribouval, Ernie L. Esquivel, Vincent Morinière, Marie-Josèphe Tête, Christophe Legendre, Patrick Niaudet, and Corinne Antignac* 571

Telomeric refinement of the *MCKD1* locus on chromosome 1q21. *Matthias T.F. Wolf, Bruno van Vlem, Hans C. Hennies, Isabella Zalewski, Stephanie M. Karle, Markus Puetz, Franziska Panther, Edgar Otto, Arno Fuchshuber, Norbert Lameire, Bart Loeys, and Friedhelm Hildebrandt* (see Editorial by Bichet and Fujiwara, p. 864)..... 580

A high prevalence of renal hypouricemia caused by inactive *SLC22A12* in Japanese. *Naoharu Iwai, Yukari Mino, Makoto Hosoyamada, Naomi Tago, Yoshihiro Kokubo, and Hitoshi Endou* 935

In vivo expression of podocyte slit diaphragm-associated proteins in nephrotic patients with *NPHS2* mutation. *Shao-Yu Zhang, Arnaud Marlier, Olivier Gribouval, Thierry Gilbert, Laurence Heidet, Corinne Antignac, and Marie Claire Gubler*..... 945

Two novel *ADAMTS13* gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS). *Christoph Licht, Ludwig Stapenhorst, Thorsten Simon, Ulrich Budde, Reinhard Schneppenheim, and Bernd Hoppe* 955

Evaluation of mutation screening as a first line test for the diagnosis of the primary hyperoxalurias. *Gill Rumsby, Emma Williams, and Marion Coulter-Mackie* 959

Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells. *Franck A. Belibi, Gail Reif, Darren P. Wallace, Tamio Yamaguchi, Lincoln Olsen, Hong Li, George M. Helmkamp, Jr., and Jared J. Grantham* (see Editorial by Torres, p. 1283)..... 964

Mutations in the uromodulin gene decrease urinary excretion of Tamm-Horsfall protein. *Anthony J. Bleyer, Thomas C. Hart, Zak Shihabi, Vicki Robins, and John R. Hoyer* 974

Parapelvic kidney cysts: A distinguishing feature with high prevalence in Fabry disease. *Markus Ries, Karen E. Bove Bettis, Peter Choyke, Jeffrey B. Kopp, Howard A. Austin III, Roscoe O. Brady, and Raphael Schiffmann*..... 978

Polyductin, the *PKHD1* gene product, comprises isoforms expressed in plasma membrane, primary cilium, and cytoplasm. *Luís F.C. Menezes, Yiqiang Cai, Yasuyuki Nagasawa, Ana M.G. Silva, Mary L. Watkins, Aline M. da Silva, Stefan Somlo, Lisa M. Guay-Woodford, Gregory G. Germino, and Luiz F. Onuchic* 1345

Fibronectin induces ureteric bud cells branching and cellular cord and tubule formation. *Peng Ye, Samy L. Habib, Jill M. Ricono, Nam-Ho Kim, Goutam G. Choudhury, Jeffrey L. Barnes, Hanna E. Abboud, and Mazen Y. Arar*..... 1356

Disease-causing missense mutations in *NPHS2* gene alter normal nephrin trafficking to the plasma membrane. *Yukino Nishibori, Li Liu, Makoto Hosoyamada, Hitoshi Endou, Akihiko Kudo, Hitoshi Takenaka, Eiji Higashihara, Fumio Bessho, Shori Takahashi, David Kershaw, Vesa Ruotsalainen, Karl Tryggvason, Jamshid Khoshnoodi, and Kunimasa Yan* 1755

Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats. *Vicente E. Torres, William E. Sweeney, Jr., Xiaofang Wang, Qi Qian, Peter C. Harris, Philip Frost, and Ellis D. Avner*..... 1766

Comparison between siblings and twins supports a role for modifier genes in ADPKD. *Alexandre Persu, Michel Duyme, Yves Pirson, Xosé M. Lens, Thierry Messiaen, Martijn H. Breuning, Dominique Chauveau, Micheline Levy, Jean-Pierre Grünfeld, and Olivier Devuyst* 2132

HORMONES – CYTOKINES – SIGNALING

Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease. *Alicia Marchlewska, Peter Stenvinkel, Bengt Lindholm, Anders Danielsson, Roberto Pecoits-Filho, Fredrik Lönnqvist, Martin Schalling, Olof Heimbürger, and Louise Nordfors* 46

Chondromodulin-I expression in the growth plate of young uremic rats. *Benito Amil, Marta Fernandez-Fuente, Ines Molinos, Julian Rodriguez, Eduardo Carbajo-Pérez, Enrique Garcia, Tadashi Yamamoto, and Fernando Santos* 51

DNAzyme for TGF-β suppressed extracellular matrix accumulation in experimental glomerulonephritis. *Yoshitaka Isaka, Hiroyuki Nakamura, Masayuki Mizui, Yoshitsugu Takabatake, Masaru Horio, Hiroshi Kawachi, Fujio Shimizu, Enyu Imai, and Masatsugu Hori* 586

Impairment of phenylalanine conversion to tyrosine in end-stage renal disease causing tyrosine deficiency. *Yves Boirie, Robert Albright, Maureen Bigelow, and K. Sreekumaran Nair* 591

Smad3 deficiency attenuates renal fibrosis, inflammation, and apoptosis after unilateral ureteral obstruction. *Kumi Inazaki, Yutaka Kanamaru, Yuko Kojima, Noriyoshi Sueyoshi, Ko Okumura, Kazunari Kaneko, Yuichiro Yamashiro, Hideoki Ogawa, and Atsuhito Nakao* 597

Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivo. *Nimesh S.A. Patel, Edward J. Sharples, Salvatore Cuzzocrea, Prabal K. Chatterjee, Domenico Britti, Muhammad M. Yaqoob, and Christoph Thiemermann* 983

Liposome-mediated transfer of nitric oxide synthase gene improves renal function in ureteral obstruction in rats. *Keiichi Ito, Jie Chen, Jonathan J. Khodadadian, Surya V. Seshan, Christian Eaton, Xinyu Zhao, E. Darracott Vaughan, Jr., Michael Lipkowitz, Dix P. Poppas, and Diane Felsen* (see Editorial by Chevalier, p. 1709) 1365

TNF-α and IL-1β–mediated regulation of MMP-9 and TIMP-1 in renal proximal tubular cells. *Larine E. Nee, Tara McMorrow, Eric Campbell, Craig Slattery, and Michael P. Ryan* 1376

Urinary excretion of aquaporin-2 water channel exaggerated dependent upon vasopressin in congestive heart failure. *Hiroshi Funayama, Tomohiro Nakamura, Takako Saito, Akio Yoshimura, Muneyasu Saito, Masanobu Kawakami, and San-e Ishikawa* (see Editorial by Gross, p. 1707) 1387

Combining TGF-β inhibition and angiotensin II blockade results in enhanced antifibrotic effect. *Ling Yu, Wayne A. Border, Ian Anderson, Matthew McCourt, Yufeng Huang, and Nancy A. Noble* 1774

Expression of somatostatin in the adult and developing mouse kidney. *Carlton M. Bates, Heather Kegg, and Sandy Grady* 1785

Caveolin-1 in mesangial cells suppresses MAP kinase activation and cell proliferation induced by bFGF and PDGF. *Yutaka Fujita, Shoichi Maruyama, Hiroshi Kogo, Seiichi Matsuo, and Toyoshi Fujimoto*. 1794

Epidermal growth factor receptor inhibition attenuates early kidney enlargement in experimental diabetes. *Lesley Wassef, Darren J. Kelly, and Richard E. Gilbert*..... 1805

AGEs activate mesangial TGF-β– Smad signaling via an angiotensin II type I receptor interaction. *Kei Fukami, Seiji Ueda, Sho-ichi Yamagishi, Seiya Kato, Yosuke Inagaki, Masayoshi Takeuchi, Yoshihiro Motomiya, Richard Bucala, Shuji Iida, Kiyoshi Tamaki, Tsutomu Imaizumi, Mark E. Cooper, and Seiya Okuda* 2137

Estradiol reverses renal injury in Alb/TGF-β1 transgenic mice. *Joel Blush, Jun Lei, Wenjun Ju, Sharon Silbiger, James Pullman, and Joel Neugarten* 2148

High calcium diet down-regulates kidney angiotensin-converting enzyme in experimental renal failure. *Ilkka Pörsti, Meng Fan, Peeter Kööbi, Pasi Jolma, Jarkko Kalliovalkama, Tuija I. Vehmas, Heikki Helin, Harry Holthöfer, Eero Mervaala, Tuulikki Nyman, and Ilkka Tikkanen* 2155

D_1 dopamine receptor signaling involves caveolin-2 in HEK-293 cells. *Peiying Yu, Zhiwei Yang, John E. Jones, Zheng Wang, Shaun A. Owens, Susette C. Mueller, Robin A. Felder, and Pedro A. Jose* 2167

Angiotensin II stimulates Pax-2 in rat kidney proximal tubular cells: Impact on proliferation and apoptosis. *Shao-Ling Zhang, Jun Guo, Babak Moini, and Julie R. Ingelfinger* 2181

CELL BIOLOGY – IMMUNOLOGY – PATHOLOGY

Decreased expression of T-cell NF-κB p65 subunit in steroid-resistant nephrotic syndrome. *Diego H. Aviles, V. Matti Vehaskari, Jennifer Manning, Augusto C. Ochoa, and Arnold H. Zea* 60

Plasmin is not protective in experimental renal interstitial fibrosis. *Kristy L. Edgtton, Renae M. Gow, Darren J. Kelly, Peter Carmeliet, and A. Richard Kitching* (see Editorial by Zheng and Harris, p. 455) 68

A pathophysiologic study of the kidney tubule to optimize organ preservation solutions. *Niaz Ahmad, Lutz Hostert, Julian R. Pratt, Katharine J. Billar, David J. Potts, and J. Peter A. Lodge* 77

Stable expression of nephrin and localization to cell-cell contacts in novel murine podocyte cell lines. *Daniel Schiwek, Nicole Endlich, Lawrence Holzman, Harry Holthöfer, Wilhelm Kriz, and Karlhans Endlich* 91

DDR1-deficient mice show localized subepithelial GBM thickening with focal loss of slit diaphragms and proteinuria. *Oliver Gross, Bogdan Beirowski, Scott J. Harvey, Catherine McFadden, Dilys Chen, Stephanie Tam, Paul S. Thorner, Neil Smyth, Klaus Addicks, Wilhelm Bloch, Yoshifumi Ninomiya, Yoshikazu Sado, Manfred Weber, and Wolfgang F. Vogel* 102

Curcumin blocks multiple sites of the TGF-β signaling cascade in renal cells. *Jens Gaedeke, Nancy A. Noble, and Wayne A. Border* 112

Staphylococcus aureus cell envelope antigen is a new candidate for the induction of IgA nephropathy. *Akio Koyama, Samina Sharmin, Hideko Sakurai, Yoshio Shimizu, Kouichi Hirayama, Joichi Usui, Michio Nagata, Keigyou Yoh, Kunihiro Yamagata, Kaori Muro, Masaki Kobayashi, Kaori Ohtani, Takeshi Shimizu, and Tohru Shimizu* 121

Proteinuria in rats induced by serum from patients with collapsing glomerulopathy. *Maria del Carmen Avila-Casado, Israel Perez-Torres, Ari Auron, Virgilia Soto, Teresa I. Fortoul, and Jaime Herrera-Acosta* 133

Parenteral iron nephrotoxicity: Potential mechanisms and consequences. *Richard A. Zager, Ali C.M. Johnson, and Sherry Y. Hanson* (see Editorial by Alam et al, p. 457) 144

Glomerular expression of the ATP-sensitive $P2X_7$ receptor in diabetic and hypertensive rat models. *Oliver Vonend, Clare M. Turner, Choong M. Chan, Andrew Loesch, G. Carmen Dell'Anna, Kaila S. Srai, Geoffrey Burnstock, and Robert J. Unwin* 157

Altered NMDA receptor expression in renal toxicity: Protection with a receptor antagonist. *Jocelyn C. Leung, Tara Marphis, Randall D. Craver, and Douglas M. Silverstein* 167

High nephritogenicity of monoclonal antibodies belonging to IgG2a and IgG2b subclasses in rat anti-GBM nephritis. *Takayuki Kohda, Shin-ichi Okada, Atsushi Hayashi, Susumu Kanzaki, Yoshifumi Ninomiya, Masafumi Taki, and Yoshikazu Sado* 177

Differential effects of simvastatin on mesangial cells. *Juliane Heusinger-Ribeiro, Barbara Fischer, and Margarete Goppelt-Struebe* 187

TGF-β induces proangiogenic and antiangiogenic factors via parallel but distinct Smad pathways. *Takahiko Nakagawa, Jin H. Li, Gabriela Garcia, Wei Mu, Ester Piek, Erwin P. Böttinger, Yan Chen, Hong J. Zhu, Duk-Hee Kang, George F. Schreiner, Hui Y. Lan, and Richard J. Johnson* (see Editorial by Woolf, p. 862) 605

Peripheral blood dendritic cells and GM-CSF as an adjuvant for hepatitis B vaccination in hemodialysis patients. *Martijn A. Verkade, Jacqueline van de Wetering, Mariska Klepper, Leonard M.B. Vaessen, Willem Weimar, and Michiel G.H. Betjes* 614

Mesangial cell expression of proto-oncogene *Ets-1* during progression of mesangioproliferative glomerulonephritis. *Ute Raffetseder, Nico Wernert, Tammo Ostendorf, Claudia van Roeyen, Thomas Rauen, Peter Behrens, Jurgen Floege, and Peter R. Mertens* 622

Dopamine D_2-like receptor agonist bromocriptine protects against ischemia/reperfusion injury in rat kidney. *Vihang Narkar, Oksana Kunduzova, Tahir Hussain, Claudie Cambon, Angelo Parini, and Mustafa Lokhandwala* 633

Uremia causes endothelial progenitor cell deficiency. *Kirsten de Groot, Ferdinand Hermann Bahlmann, Johanna Sowa, Jana Koenig, Jan Menne, Hermann Haller, and Danilo Fliser* 641

Fibrin independent proinflammatory effects of tissue factor in experimental crescentic glomerulonephritis. *Malcolm A. Cunningham, A. Richard Kitching, Peter G. Tipping, and Stephen R. Holdsworth* 647

Proximal tubule cells stimulated by lipopolysaccharide inhibit macrophage activation. *Yiping Wang, Yuet-Ching Tay, and David C.H. Harris* 655

Estimation of podocyte number: A comparison of methods. *Kathryn Elizabeth White and Rudolf William Bilous* 663

AT-1 receptor blockade prevents proteinuria, renal failure, hyperlipidemia, and glomerulosclerosis in the Imai rat. *Bernardo Rodríguez-Iturbe, Tadashi Sato, Yasmir Quiroz, and Nosratola D. Vaziri* 668

Renal proximal tubular cells acquire resistance to cell death stimuli in mice with hereditary tyrosinemia type 1. *Marjanka C. Luijerink, Ellen A.C.M. van Beurden, Helga E.M. Malingré, Saskia M.M. Jacobs, Markus Grompe, Leo W.J. Klomp, Ruud Berger, and Inge E.T. van den Berg* 990

C-type natriuretic peptide as a podocyte hormone and modulation of its cGMP production by glucose and mechanical stress. *Barbara Lewko, Nicole Endlich, Wilhelm Kriz, Jan Stepinski, and Karlhans Endlich* 1001

Autoantibodies to neutrophil cytoplasmic antigens (ANCA) do not bind to polymorphonuclear neutrophils in blood. *Bahaa Abdel-Salam, Christof Iking-Konert, Matthias Schneider, Konrad Andrassy, and G. Maria Hänsch* 1009

Retinoic acid treatment protects MRL/lpr lupus mice from the development of glomerular disease. *Guillermo Pérez de Lema, Francisco Javier Lucio-Cazaña, Ana Molina, Bruno Luckow, Holger Schmid, Cor de Wit, Victoria Moreno-Manzano, Bernhard Banas, Francisco Mampaso, and Detlef Schlöndorff* 1018

Renal phenotype is exacerbated in *Os* and *lpr* double mutant mice. *George Jarad, Sujata Lakhe-Reddy, Jeffrey Blatnik, Morgan Koepke, Shenaz Khan, M. Ashraf El-Meanawy, Andrew S. O'Connor, John R. Sedor, and Jeffrey R. Schelling* 1029

The role of lymphocytes in the experimental progressive glomerulonephritis. *Yohei Ikezumi, Katsue Kanno, Tamaki Karasawa, Gi Dong Han, Yumi Ito, Hiroko Koike, Shinichi Toyabe, Makoto Uchiyama, Fujio Shimizu, and Hiroshi Kawachi* 1036

Wegener's granulomatosis is associated with organ-specific antiendothelial cell antibodies. *Carolina Holmén, Marta Christensson, Erna Pettersson, Johan Bratt, Pär Stjärne, Azza Karrar, and Suchitra Sumitran-Holgersson* 1049

Recombinant uteroglobin prevents the experimental crescentic glomerulonephritis. *Dong-Sup Lee, Seung Hee Yang, Hyun Lee Kim, Kwon Wook Joo, Chun Soo Lim, Dong-Wan Chae, Suhnggwon Kim, Jung Sang Lee, and Yon Su Kim* 1061

Hyperlipidemia aggravates renal disease in B6.ROP Os/+ mice. *Anja S. Mühlfeld, Min W. Spencer, Kelly L. Hudkins, Elizabeth Kirk, Renee C. LeBoeuf, and Charles E. Alpers* 1393

Mesangial expression of angiotensin II receptor in IgA nephropathy and its regulation by polymeric IgA1. *Kar Neng Lai, Loretta Y.Y. Chan, Sydney C.W. Tang, Anita W.L. Tsang, Felix F.K. Li, Man Fai Lam, Sing Leung Lui, and Joseph C.K. Leung* 1403

Hyperexpression of the granzyme B inhibitor PI-9 in human renal allografts: A potential mechanism for stable renal function in patients with subclinical rejection. *Ajda T. Rowshani, Sandrine Florquin, Frederike Bemelman, J. Alain Kummer, C. Erik Hack, and Ineke J.M. ten Berge* 1417

$\alpha_v\beta_6$ integrin expression in diseased and transplanted kidneys. *Paul Trevillian, Helen Paul, Ewan Millar, Adrian Hibberd, and Michael V. Agrez* 1423

Selective lymphocyte inhibition by FTY720 slows the progressive course of chronic anti-thy 1 glomerulosclerosis. *Harm Peters, Sebastian Martini, Yingrui Wang, Fuijo Shimizu, Hiroshi Kawachi, Stephanie Krämer, and Hans-H. Neumayer* 1434

Blockade of the CD154-CD40 costimulatory pathway prevents the development of experimental autoimmune glomerulonephritis. *John Reynolds, Sarah B. Khan, Andrew R. Allen, Christopher D. Benjamin, and Charles D. Pusey* 1444

The renin-angiotensin system blockade does not prevent renal interstitial fibrosis induced by aristolochic acids. *Frédéric D. Debelle, Joëlle L. Nortier, Cécile P. Husson, Eric G. De Prez, Anne R. Vienne, Katja Rombaut, Isabelle J. Salmon, Monique M. Deschodt-Lanckman, and Jean-Louis Vanherweghem* 1815

Gene expression profiling of anti-GBM glomerulonephritis model: The role of NF-κB in immune complex kidney disease. *Ju Han Kim, Il Soo Ha, Chang-Il Hwang, Young-Ju Lee, Jihoon Kim, Seung-Hee Yang, Yon Su Kim, Yun Anna Cao, Sangdun Choi, and Woong-Yang Park* 1826

C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis. *Gopala K. Rangan, Jeffrey W. Pippin, and William G. Couser* 1838

Albumin up-regulates the type II transforming growth factor-beta receptor in cultured proximal tubular cells. *Gunter Wolf, Regine Schroeder, Fuad N. Ziyadeh, and Rolf A.K. Stahl* (see Editorial by Imai, p. 2085) 1849

Heterozygous mice for TGF-βIIR gene are resistant to the progression of streptozotocin-induced diabetic nephropathy. *Hwal Woong Kim, Bong Cho Kim, Chi Young Song, Ji Hoon Kim, Hye Kyoung Hong, and Hyun Soon Lee* 1859

Mild hyperhomocysteinemia promotes renal hemodynamic dysfunction without histopathologic changes in adult rats. *Georgina P. Ossani, Patricia A. Fischer, Silvia G. Caram, Graciela N. Dominguez, Alberto J. Monserrat, and Lucas D. Masnatta* 1866

In vitro evidence for immune activating effect of specific AGE structures retained in uremia. *Griet Glorieux, Ruediger Helling, Thomas Henle, Philippe Brunet, Reinhold Deppisch, Norbert Lameire, and Raymond Vanholder* 1873

Induction of antioxidant enzymes in murine podocytes precedes injury by puromycin aminonucleoside. *Virginia Vega-Warner, Richard F. Ransom, Andrea M. Vincent, Frank C. Brosius, and William E. Smoyer* 1881

Mitochondrial dysfunction is a primary event in renal cell oxalate toxicity. *Lu-Cheng Cao, Thomas W. Honeyman, Rachel Cooney, Lori Kennington, Cheryl R. Scheid, and Julie A. Jonassen* 1890

Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. *José G. van den Berg, Marius A. van den Bergh Weerman, Karel J.M. Assmann, Jan J. Weening, and Sandrine Florquin* 1901

CCR and CC chemokine expression in relation to Flt3 ligand-induced renal dendritic cell mobilization. *P. Toby H. Coates, Bridget L. Colvin, Anju Ranganathan, F. Jason Duncan, Yuk Yuen Lan, William J. Shufesky, Alan F. Zahorchak, Adrian E. Morelli, and Angus W. Thomson* 1907

Isolation and characterization of conditionally immortalized mouse glomerular endothelial cell lines. *Angelique L. Rops, Johan van der Vlag, Cor W. Jacobs, Henry B. Dijkman, Joost F. Lensen, Tessa J. Wijnhoven, Lambert P. van den Heuvel, Toin H. van Kuppevelt, and Jo H. Berden* 2193

Caspase-1–deficient mice are protected against cisplatin-induced apoptosis and acute tubular necrosis. *Sarah Faubel, Danica Ljubanovic, Leonid Reznikov, Hilary Somerset, Charles A. Dinarello, and Charles L. Edelstein* 2202

The characterization of a specific Thy-1 molecular epitope expressed on rat mesangial cells. *Tetsuo Morioka, Jian Yao, Yasuhito Suzuki, and Takashi Oite* 2214

Expression and activity of soluble guanylate cyclase in injury and repair of anti-Thy-1 glomerulonephritis. *Harm Peters, Yingrui Wang, Tanja Loof, Sebastian Martini, Susanne Kron, Stephanie Krämer, and Hans-H. Neumayer* 2224

Adverse effects of hyperphosphatemia on myocardial hypertrophy, renal function, and bone in rats with renal failure. *Katia R. Neves, Fabiana G. Graciolli, Luciene M. dos Reis, Carlos A. Pasqualucci, Rosa M.A. Moysés, and Vanda Jorgetti* 2237

Extracellular calcium antagonizes forskolin-induced aquaporin 2 trafficking in collecting duct cells. *Giuseppe Procino, Monica Carmosino, Grazia Tamma, Sabine Gouraud, Antonia Laera, Daniela Riccardi, Maria Svelto, and Giovanna Valenti* 2245

Binding of the chemokine SLC/CCL21 to its receptor CCR7 increases adhesive properties of human mesangial cells. *Bernhard Banas, Markus Wörnle, Monika Merkle, Mercedes Gonzalez-Rubio, Holger Schmid, Matthias Kretzler, Miriam C. Pietrzyk, Monika Fink, Guillermo Perez de Lema, and Detlef Schlöndorff* 2256

CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. *Volker Vielhauer, Elias Berning, Vaclav Eis, Matthias Kretzler, Stephan Segerer, Frank Strutz, Richard Horuk, Hermann-Josef Gröne, Detlef Schlöndorff, and Hans-Joachim Anders.* 2264

ION CHANNELS – MEMBRANE TRANSPORT – INTEGRATIVE PHYSIOLOGY

Nephrotoxicity of platinum complexes is related to basolateral organic cation transport. *Thomas Ludwig, Christoph Riethmüller, Michael Gekle, Gerald Schwerdt, and Hans Oberleithner* 196

Neonatal ureteral obstruction alters expression of renal sodium transporters and aquaporin water channels. *Yimin Shi, Chunling Li, Klaus Thomsen, Troels Munch Jørgensen, Mark A. Knepper, Søren Nielsen, Jens Christian Djurhuus, and Jørgen Frøkiær* 203

Over-expression of renal LAT1 and LAT2 and enhanced L-DOPA uptake in SHR immortalized renal proximal tubular cells. *Maria João Pinho, Maria Paula Serrão, Pedro Gomes, Ulrich Hopfer, Pedro A. Jose, and P. Soares-da-Silva* 216

Ouabain induces endocytosis of plasmalemmal Na/K-ATPase in LLC-PK1 cells by a clathrin-dependent mechanism. *Jiang Liu, Riad Kesiry, Sankaridrug M. Periyasamy, Deepak Malhotra, Zijian Xie, and Joseph I. Shapiro* 227

Aldosterone enhances renal calcium reabsorption by two types of channels. *Marie Leclerc, Michèle G. Brunette, and Denis Couchourel* 242

Human organic anion transporter 1 mediates cellular uptake of cysteine-*S* conjugates of inorganic mercury. *Rudolfs K. Zalups, Amy G. Aslamkhan, and Sarfaraz Ahmad* 251

Up-regulation of hepatic Acyl CoA: Diacylglycerol acyltransferase-1 (DGAT-1) expression in nephrotic syndrome. *Nosratola D. Vaziri, Choong H. Kim, Dennis Phan, Sara Kim, and Kaihui Liang* 262

Fat malabsorption induced by gastrointestinal lipase inhibitor leads to an increase in urinary oxalate excretion. *Renato Ribeiro Nogueira Ferraz, Hans-Göran Tiselius, and Ita Pfeferman Heiberg* 676

EPO and α-MSH prevent ischemia/reperfusion-induced down-regulation of AQPs and sodium transporters in rat kidney. *Hong Gong, Weidong Wang, Tae-Hwan Kwon, Thomas Jonassen, Chunling Li, Troels Ring, Jørgen Frøkiær, and Søren Nielsen* 683

Signaling path of the action of AVP on distal K^+ secretion. *José B.O. Amorim, Raif Musa-Aziz, Margarida Mello-Aires, and Gerhard Malnic* 696

The effect of β-subunit assembly on function and localization of the colonic H^+,K^+-ATPase α-subunit. *Jian Li, Juan Codina, Elizabeth Petroske, Mike J. Werle, Mark C. Willingham, and Thomas D. DuBose, Jr.* 1068

Racial differences in potassium disposal. *Annie Suh, Ernest DeJesus, Karol Rosner, Edgar Lerma, William Yu, James B. Young, and Robert M. Rosa* 1076

Effects of vitamin D compounds on renal and intestinal Ca^{2+} transport proteins in 25-hydroxyvitamin D_3-1α-hydroxylase knockout mice. *Joost G.J. Hoenderop, Annemiete W.C.M. van der Kemp, Colleen M. Urben, Stephen A. Strugnell, and René J.M. Bindels* (see Editorial by Goodman, p. 1286)..... 1082

The amino acid transporter asc-1 is not involved in cystinuria. *Marta Pineda, Mariona Font, Maria Teresa Bassi, Marta Manzoni, Giuseppe Borsani, Valeria Marigo, Esperanza Fernández, Rafael Martín del Río, Jesús Purroy, Antonio Zorzano, Virginia Nunes, and Manuel Palacín* 1453

Regulation of CLC-Ka/barttin by the ubiquitin ligase Nedd4-2 and the serum- and glucocorticoid-dependent kinases. *Hamdy M. Embark, Christoph Böhmer, Monica Palmada, Jeyaganesh Rajamanickam, Amanda W. Wyatt, Sabine Wallisch, Giovambattista Capasso, Petra Waldegger, Hannsjörg W. Seyberth, Siegfried Waldegger, and Florian Lang*..... 1918

The relationship between cell proliferation, Cl^- secretion, and renal cyst growth: A study using CFTR inhibitors. *Hongyu Li, Iain A. Findlay, and David N. Sheppard* 1926

Fluorescent imaging of acute mercuric chloride exposure on cultured human kidney tubular epithelial cells. *Zhichao Zhang, Xiangfeng Guo, Xuhong Qian, Zhe Lu, and Fengyu Liu*..... 2279

A carboxy-terminus motif of $HK\alpha_2$ is necessary for assembly and function. *Juan Codina, Jian Li, and Thomas D. DuBose, Jr.* 2283

Elevated extracellular calcium levels induce smooth muscle cell matrix mineralization in vitro. *Hsueh Yang, Gabrielle Curinga, and Cecilia M. Giachelli* (see Editorial by Towler, p. 2467)..... 2293

Overexpression of HSP-72 confers cytoprotection in experimental peritoneal dialysis. *Bettina Bidmon, Michaela Endemann, Klaus Arbeiter, Dagmar Ruffingshofer, Heinz Regele, Kurt Herkner, Oliver Eickelberg, and Christoph Aufricht*..... 2300

Validation of internal control genes for gene expression analysis in diabetic glomerulosclerosis. *Jason Biederman, Jerry Yee, and Pedro Cortes*..... 2308

VASCULAR BIOLOGY – HEMODYNAMICS – HYPERTENSION

Superoxide enhances tubuloglomerular feedback by constricting the afferent arteriole. *Ruisheng Liu, YiLin Ren, Jeffrey L. Garvin, and Oscar A. Carretero* 268

Transvascular lipoprotein transport in patients with chronic renal disease. *Trine Krogsgaard Jensen, Børge Grønne Nordestgaard, Bo Feldt-Rasmussen, Kurt Svarre Jensen, and Jan Skov Jensen* 275

Nitric oxide and renal nerves: Comparison of effects on renal circulation and sodium excretion in anesthetized rats. *Agnieszka Walkowska, Elzbieta Kompanowska-Jezierska, and Janusz Sadowski*... 705

Cytokine gene expression profiles in kidney medulla and cortex of obese hypertensive dogs. *Jian-Wei Gu, Julie Wang, Alisha Stockton, Bradley Lokitz, Lisa Henegar, and John E. Hall* 713

Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. *Jenny J. Zhang, Grant Bledsoe, Kazuo Kato, Lee Chao, and Julie Chao* 722

Activation of mesangial cell MAPK in response to homocysteine. *Alistair J. Ingram, Joan C. Krepinsky, Leighton James, Richard C. Austin, Damu Tang, Anne Marie Salapatek, Kerri Thai, and James W. Scholey* 733

Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes. *Guorong Ma, Terri J. Allen, Mark E. Cooper, and Zemin Cao* 1090

Effect of advanced glycation end-products on gene expression and synthesis of TNF-α and endothelial nitric oxide synthase by endothelial cells. *Gloria Rashid, Sydney Benchetrit, Dina Fishman, and Jacques Bernheim* 1099

Uric acid and the state of the intrarenal renin-angiotensin system in humans. *Todd S. Perlstein, Olga Gumieniak, Paul N. Hopkins, Laine J. Murphey, Nancy J. Brown, Gordon H. Williams, Norman K. Hollenberg, and Naomi D.L. Fisher* 1465

Regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF-A) expression in podocytes. *Kaustubh Datta, Jinping Li, S. Ananth Karumanchi, Enfeng Wang, Eric Rondeau, and Debabrata Mukhopadhyay* 1471

Role of macula densa adenosine triphosphate (ATP) in tubuloglomerular feedback. *YiLin Ren, Jeffrey L. Garvin, Ruisheng Liu, and Oscar A. Carretero* 1479

Aortic pulse wave velocity in renal transplant patients. *Sola Aoun Bahous, Antoine Stephan, Wadad Barakat, Jacques Blacher, Roland Asmar, and Michel E. Safar* 1486

Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. *Genro Fujisawa, Koji Okada, Shigeaki Muto, Nobuya Fujita, Naoki Itabashi, Eiji Kusano, and Shun Ishibashi* 1493

HMG-CoA reductase, cholesterol 7α-hydroxylase, LDL receptor, SR-B1, and ACAT in diet-induced syndrome X. *Christian K. Roberts, Kaihui Liang, R. James Barnard, Choong H. Kim, and Nosratola D. Vaziri* 1503

RAPPID COMMUNICATION Static intra-access pressure ratio does not correlate with access blood flow. *Lawrence M. Spergel, Janet E. Holland, Stephen Z. Fadem, Charles J. McAllister, and Eileen J. Peacock* 1512

Real-time observation of glomerular hemodynamic changes in diabetic rats: Effects of insulin and ARB. *Bing Li, Jian Yao, Kazuko Kawamura, Yukiko Oyanagi-Tanaka, Mari Hoshiyama, Tetsuo Morioka, Fumitake Gejyo, Makoto Uchiyama, and Takashi Oite* 1939

AT1 receptors mediate angiotensin II–induced release of nitric oxide in afferent arterioles. *Andreas Patzak, En Y. Lai, Ralf Mrowka, Andreas Steege, Pontus B. Persson, and A. Erik G. Persson* 1949

Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. *Ariela Benigni, Carla Zoja, Cristina Zatelli, Daniela Corna, Lorena Longaretti, Daniela Rottoli, Paola Maggioni, Marta Todeschini, Marina Noris, and Giuseppe Remuzzi* 1959

Ovariectomy enhances renal cortical expression and function of cyclooxygenase-2. *Yuko Tada, Atsuhiro Ichihara, Yukako Koura, Hirokazu Okada, Yuki Kaneshiro, Matsuhiko Hayashi, and Takao Saruta* 1966

Homocysteine activates NADH/NADPH oxidase through ceramide-stimulated Rac GTPase activity in rat mesangial cells. *Fan Yi, Andrew Y. Zhang, Jennifer L. Janscha, Pin-Lan Li, and Ai-Ping Zou* .. 1977

Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats. *Xiaoxia Wang, Kaushik Desai, Jes Thorn Clausen, and Lingyun Wu* 2315

Evidence for compromised aldosterone synthase enzyme activity in preeclampsia. *Kushiar Shojaati, Maja Causevic, Bert Kadereit, Bernhard Dick, Jeanine Imobersteg, Henning Schneider, Ernst Beinder, Maki Kashiwagi, Brigitte M. Frey, Felix J. Frey, and Markus G. Mohaupt* 2322

Lead exposure raises superoxide and hydrogen peroxide in human endothelial and vascular smooth muscle cells. *Zhenmin Ni, Stephen Hou, Cyril H. Barton, and Nosratola D. Vaziri* 2329

Endothelial dysfunction as a modifier of angiogenic response in Zucker diabetic fat rat: Amelioration with Ebselen. *Olga Gealekman, Sergey V. Brodsky, Fan Zhang, Praveen N. Chander, Caline Friedli, Alberto Nasjletti, and Michael S. Goligorsky* 2337

Temporal adaptation of tubuloglomerular feedback: Effects of COX-2. *Aihua Deng, Lucinda M. Wead, and Roland C. Blantz* 2348

CLINICAL NEPHROLOGY – EPIDEMIOLOGY – CLINICAL TRIALS

Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. *Daniel I. Feig, Takahiko Nakagawa, S. Ananth Karumanchi, William J. Oliver, Duk-Hee Kang, Jennifer Finch, and Richard J. Johnson* 281

Association of interleukin-10 gene G-1082A polymorphism with the progression of primary glomerulonephritis. *Christos Bantis, Peter J. Heering, Sendogan Aker, Nicola Klein-Vehne, Bernd Grabensee, and Katrin Ivens* 288

Dose-dependent effect of parenteral iron therapy on bleomycin-detectable iron in immune apheresis patients. *Gürkan Sengoelge, Verena Rainer, Josef Kletzmayr, Martin Jansen, Kurt Derfler, Manuela Födinger, Walter H. Hörl, and Gere Sunder-Plassmann* 295

Association between serum homocysteine and markers of impaired kidney function in adults in the United States. *Mildred E. Francis, Paul W. Eggers, Thomas H. Hostetter, and Josephine P. Briggs* 303

Chronic kidney disease: The distribution of health care dollars. *Wendy L. St. Peter, Samina S. Khan, James P. Ebben, Brian J.G. Pereira, and Allan J. Collins* 313

G protein β3 subunit C825T polymorphism in primary IgA nephropathy. *Lise Thibaudin, Patricia Berthoux, Damien Thibaudin, Christophe Mariat, and François Berthoux* 322

Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. *Solbjørg Sagedal, Anders Hartmann, Knut P. Nordal, Kåre Osnes, Torbjørn Leivestad, Aksel Foss, Miklos Degré, Per Fauchald, and Halvor Rollag* 329

Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. *Martin Busch, Sybille Franke, Andreas Müller, Marco Wolf, Jens Gerth, Undine Ott, Toshimitsu Niwa, and Günter Stein* 338

Lipoprotein(a)- and low-density lipoprotein–derived cholesterol in nephrotic syndrome: Impact on lipid-lowering therapy? *Florian Kronenberg, Arno Lingenhel, Karl Lhotta, Barbara Rantner, Martina F. Kronenberg, Paul König, Joachim Thiery, Michael Koch, Arnold von Eckardstein, and Hans Dieplinger* 348

Effects of hemodialysis dose and membrane flux on health-related quality of life in the HEMO Study. *Mark Unruh, Robert Benz, Tom Greene, Guofen Yan, Srinivasan Beddhu, Maria DeVita, Johanna T. Dwyer, Paul L. Kimmel, John W. Kusek, Alice Martin, Josephine Rehm-McGillicuddy, Brendan P. Teehan, Klemens B. Meyer, and The HEMO Study Group* 355

Clinical implications of mutation analysis in primary hyperoxaluria type 1. *Christiaan S. van Woerden, Jaap W. Groothoff, Frits A. Wijburg, Carla Annink, Ronald J.A. Wanders, and Hans R. Waterham* ... 746

Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. *Chariclia Gouva, Petros Nikolopoulos, John P.A. Ioannidis, and Kostas C. Siamopoulos* 753

The urine-blood PCO_2 gradient as a diagnostic index of H^+-ATPase defect distal renal tubular acidosis. *Sejoong Kim, Jay Wook Lee, Junghwan Park, Ki Young Na, Kwon Wook Joo, Curie Ahn, Suhnggwon Kim, Jung Sang Lee, Gheun-Ho Kim, Jin Kim, and Jin Suk Han* 761

Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure. *Elke Wühl, Otto Mehls, Franz Schaefer, and the ESCAPE Trial Group* 768

Clinical implications of abundant calcium phosphate in routinely analyzed kidney stones. *Joan H. Parks, Elaine M. Worcester, Fredric L. Coe, Andrew P. Evan, and James E. Lingeman* 777

High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy. *Masao Toyoda, Daisuke Suzuki, Masashi Honma, Goro Uehara, Takako Sakai, Tomoya Umezono, and Hideto Sakai* 1107

Early detection of acute renal failure by serum cystatin C. *Stefan Herget-Rosenthal, Günter Marggraf, Johannes Hüsing, Frauke Göring, Frank Pietruck, Onno Janssen, Thomas Philipp, and Andreas Kribben* 1115

Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. *Marcello Tonelli, Dorothea Collins, Sander Robins, Hanna Bloomfield, and Gary C. Curhan, for the Veterans' Affairs High-Density Lipoprotein Intervention Trial (VA-HIT) Investigators* 1123

Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. *Anupama Mohanram, Zhongxin Zhang, Shahnaz Shahinfar, William F. Keane, Barry M. Brenner, and Robert D. Toto* 1131

Transferrin saturation with intravenous irons: An in vitro study. *Rajiv Agarwal* 1139

The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection. *Lynda Anne Szczech, Samir K. Gupta, Ramez Habash, Antonio Guasch, Robert Kalayjian, Richard Appel, Timothy A. Fields, Laura P. Svetkey, Katherine H. Flanagan, Paul E. Klotman, and Jonathan A. Winston* 1145

Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies. *Hassane Izzedine, Jean Sebastien Hulot, Vincent Launay-Vacher, Patrick Marcellini, Stephanos J. Hadziyannis, Graham Currie, Carol L. Brosgart, Chris Westland, Sarah Arterbrun, and Gilbert Deray, for the Adefovir Dipivoxil International 437 and 438 Study Groups* 1153

Tamm-Horsfall protein is a critical renal defense factor protecting against calcium oxalate crystal formation. *Lan Mo, Hong-Ying Huang, Xin-Hua Zhu, Ellen Shapiro, David L. Hasty, and Xue-Ru Wu* 1159

Low-molecular-weight AGEs are associated with GFR and anemia in patients with type 2 diabetes. *Merlin C. Thomas, Con Tsalamandris, Richard MacIsaac, Tanya Medley, Bronwyn Kingwell, Mark E. Cooper, and George Jerums* 1167

Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26. *Michael Cusick, Emily Y. Chew, Byron Hoogwerf, Elvira Agrón, LieLing Wu, Anna Lindley, Frederick L. Ferris III, and The Early Treatment Diabetic Retinopathy Study Research Group* 1173

Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy. *Peter Hovind, Lise Tarnow, Peter Rossing, Bendix Carstensen, and Hans-Henrik Parving* 1180

Duffy antigen receptor and genetic susceptibility of African Americans to acute rejection and delayed function. *Kevin C. Mange, Eline Luning Prak, Malek Kamoun, Yangzhu Du, Noah Goodman, Theodore Danoff, Tracey Hoy, Melissa Newman, Marshall M. Joffe, and Harold I. Feldman* 1187

Iron sucrose in hemodialysis patients: Safety of replacement and maintenance regimens. *George R. Aronoff, William M. Bennett, Samuel Blumenthal, Chaim Charytan, J. Phillip Pennell, John Reed, Marcos Rothstein, James Strom, Anthony Wolfe, David Van Wyck, and Jerry Yee, for the United States Iron Sucrose (Venofer®) Clinical Trials Group* 1193

Idiopathic membranous nephropathy: Definition and relevance of a partial remission. *Stéphan Troyanov, Catherine A. Wall, Judith A. Miller, James W. Scholey, and Daniel C. Cattran, for the Toronto Glomerulonephritis Registry Group* 1199

Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. *Thomas Fehr, Peter Ammann, Daniela Garzoni, Wolfgang Korte, Walter Fierz, Hans Rickli, and Rudolf P. Wüthrich* 1206

A genome scan for diabetic nephropathy in African Americans. *Donald W. Bowden, Carla J. Colicigno, Carl D. Langefeld, Michèle M. Sale, Adrienne Williams, Pamela J. Anderson, Stephen S. Rich, and Barry I. Freedman* 1517

Impact of hemodialysis on endogenous plasma and muscle carnitine levels in patients with end-stage renal disease. *Allan M. Evans, Randall J. Faull, Roger L. Nation, Shilpanjali Prasad, Tony Elias, Stephanie E. Reuter, and Gianfranco Fornasini* 1527

Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. *Jeremy B. Levy, Tarig Hammad, Anne Coulthart, Tammy Dougan, and Charles D. Pusey* 1535

Pediatric acute renal failure in Southwestern Nigeria. *Wasiu A. Olowu and Kayode A. Adelusola* ... 1541

Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. *Bengt Fellström, Hallvard Holdaas, Alan G. Jardine, Ingar Holme, Gudrun Nyberg, Per Fauchald, Carola Grönhagen-Riska, Søren Madsen, Hans-Hellmut Neumayer, Edward Cole, Bart Maes, Patrice Ambühl, Anders G. Olsson, Anders Hartmann, John O. Logan, Terje R. Pedersen, on behalf of the Assessment of Lescol in Renal Transplantation (ALERT) Study Investigators* 1549

Cationic charge-preferential IgG reabsorption in the renal proximal tubules. *Shori Takahashi, Naohiro Wada, Kensuke Harada, and Michio Nagata* 1556

Pain patterns in patients with polycystic kidney disease. *Zahid H. Bajwa, Khuram A. Sial, Atif B. Malik, and Theodore I. Steinman* 1561

Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy. *Carlo Manno, Giovanni F.M. Strippoli, Loredana Arnesano, Carmen Bonifati, Nicla Campobasso, Loreto Gesualdo, and Francesco P. Schena* 1570

Initial clinical results of the bioartificial kidney containing human cells in ICU patients with acute renal failure. *H. David Humes, William F. Weitzel, Robert H. Bartlett, Fresca C. Swaniker, Emil P. Paganini, Jack R. Luderer, and Joseph Sobota* 1578

Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta. *Gabor E. Linthorst, Carla E.M. Hollak, Wilma E. Donker-Koopman, Anneke Strijland, and Johannes M.F.G. Aerts* 1589

Progression of nephropathy in type 2 diabetic patients. *Kasper Rossing, Per K. Christensen, Peter Hovind, Lise Tarnow, Peter Rossing, and Hans-Henrik Parving* 1596

Early prediction of IgA nephropathy progression: Proteinuria and AOPP are strong prognostic markers. *Béatrice Descamps-Latscha, Véronique Witko-Sarsat, Thao Nguyen-Khoa, Anh Thu Nguyen, Valérie Gausson, Nadya Mothu, Camila Cardoso, Laure-Hélène Noël, Alain P. Guérin, Gérard M. London, and Paul Jungers* 1606

Spectrum of acute renal failure in the intensive care unit: The PICARD experience. *Ravindra L. Mehta, Maria T. Pascual, Sharon Soroko, Brandon R. Savage, Jonathan Himmelfarb, T. Alp Ikizler, Emil P. Paganini, and Glenn M. Chertow, for the Program to Improve Care in Acute Renal Disease (PICARD)* 1613

Oxidative stress is enhanced in correlation with renal dysfunction: Examination with the redox state of albumin. *Hiroyuki Terawaki, Kazunobu Yoshimura, Toshio Hasegawa, Yukie Matsuyama, Tsuneo Negawa, Kenichi Yamada, Masato Matsushima, Masaaki Nakayama, Tatsuo Hosoya, and Seiichi Era* 1988

Quantitative amino acid and proteomic analysis: Very low excretion of polypeptides >750 Da in normal urine. *Anthony G.W. Norden, Peter Sharratt, Pedro R. Cutillas, Rainer Cramer, Sharon C. Gardner, and Robert J. Unwin* 1994

Kidney and anemia in familial amyloidosis type I. *Idalina Beirão, Luísa Lobato, Paulo M.P. Costa, Isabel Fonseca, Paula Mendes, Manuela Silva, Fernanda Bravo, António Cabrita, and Graça Porto*... 2004

Survival following parathyroidectomy among United States dialysis patients. *Bryan Kestenbaum, Dennis L. Andress, Stephen M. Schwartz, Daniel L. Gillen, Stephen L. Seliger, Paresh R. Jadav, Donald J. Sherrard, and Catherine Stehman-Breen* 2010

Kidney function is inversely associated with coronary artery calcification in men and women free of cardiovascular disease: The Framingham Heart Study. *Caroline S. Fox, Martin G. Larson, Michelle J. Keyes, Daniel Levy, Melvin E. Clouse, Bruce Culleton, and Christopher J. O'Donnell* 2017

Determinants of coronary artery calcification in diabetics with and without nephropathy. *Rajnish Mehrotra, Matthew Budoff, Peter Christenson, Eli Ipp, Junichiro Takasu, Ajay Gupta, Keith Norris, and Sharon Adler* 2022

RAPID COMMUNICATION: Relative effect of urinary calcium and oxalate on saturation of calcium oxalate. *Charles Y.C. Pak, Beverley Adams-Huet, John R. Poindexter, Margaret S. Pearle, Roy D. Peterson, and Orson W. Moe* 2032

Impaired monocyte cytokine production in critically ill patients with acute renal failure. *Jonathan Himmelfarb, Phuong Le, Jennifer Klenzak, Stephanie Freedman, M. Elizabeth McMenamin, T. Alp Ikizler, and the PICARD Group* 2354

Validation of the Kidney Disease Quality of Life (KDQOL) Cognitive Function subscale. *Manjula Kurella, Jennifer Luan, Kristine Yaffe, and Glenn M. Chertow* 2361

Creatinine levels among Mexican Americans, Puerto Ricans, and Cuban Americans in the Hispanic Health and Nutrition Examination Survey. *Rudolph A. Rodriguez, German T. Hernandez, Ann M. O'Hare, David V. Glidden, and Eliseo J. Pérez-Stable* 2368

Predictive value of urinary micro-cholesterol (mCHO) levels in patients with progressive glomerular disease. *Osamu Hotta, Hisako Sugai, Hiroshi Kitamura, Naoko Yusa, and Yoshio Taguma* 2374

The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. *Hitoshi Yokoyama, Takashi Wada, Akinori Hara, Junya Yamahana, Izaya Nakaya, Motoo Kobayashi, Kiyoki Kitagawa, Satoshi Kokubo, Yasunori Iwata, Keiichi Yoshimoto, Kazuaki Shimizu, Norihiko Sakai, Kengo Furuichi, and The Kanazawa Study Group for Renal Diseases and Hypertension* 2382

The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. *Edward F. Vonesh, Jon J. Snyder, Robert N. Foley, and Allan J. Collins* 2389

The effect of fruits and vegetables on urinary stone risk factors. *Tiziana Meschi, Umberto Maggiore, Enrico Fiaccadori, Tania Schianchi, Simone Bosi, Giuditta Adorni, Erminia Ridolo, Angela Guerra, Franca Allegri, Almerico Novarini, and Loris Borghi* 2402

Mycophenolate therapy of SLE membranous nephropathy. *Dan N. Spetie, Yuxiao Tang, Brad H. Rovin, Tibor Nadasdy, Gyongyi Nadasdy, Todd E. Pesavento, and Lee A. Hebert* 2411

DIALYSIS – TRANSPLANTATION

The pharmacokinetics and hemodynamics of sildenafil citrate in male hemodialysis patients. *Eric B. Grossman, Suzanne K. Swan, Gary J. Muirhead, Michael Gaffney, Menger Chung, Herb DeRiesthal, Diane Chow, and Leopoldo Raij* 367

The willingness of patients to accept an additional mortality risk in order to improve renal graft survival. *Vincenzo Girardi, Franziska Schaedeli, Hans-Peter Marti, Felix J. Frey, and Dominik E. Uehlinger* ... 375

Risk of malignancy with long-term immunosuppression in renal transplant recipients. *Mahendra L. Agraharkar, Robert D. Cinclair, Yong-fang Kuo, John A. Daller, and Vahakn B. Shahinian* 383

Randomized controlled trial of prophylactic repair of hemodialysis arteriovenous graft stenosis. *Laura M. Dember, Erika F. Holmberg, and James S. Kaufman* 390

Usefulness of artificial neural networks to predict follow-up dietary protein intake in hemodialysis patients. *Luca Gabutti, Michel Burnier, Giorgio Mombelli, Francesca Malé, Lisa Pellegrini, and Claudio Marone* 399

The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. *John D. Williams, Nicholas Topley, Kathrine J. Craig, Ruth K. Mackenzie, Monika Pischetsrieder, Cristina Lage, and Jutta Passlick-Deetjen, on behalf of the Euro-Balance Trial Group* 408

Transforming growth factor-beta 1 gene polymorphisms and cardiovascular disease in hemodialysis patients. *Madhumathi Rao, Daqing Guo, Bertrand L. Jaber, Hocine Tighiouart, Brian J.G. Pereira, Vaidyanathapuram S. Balakrishnan, and The HEMO Study Group* 419

Nonimmunologic complications and gene polymorphisms of immunoregulatory cytokines in long-term renal transplants. *Nina Babel, Georgiy Cherepnev, Alexander Kowalenko, Jan Horstrup, Hans-Dieter Volk, and Petra Reinke* 428

Alterations of CYP3A4 and P-glycoprotein activity in vivo with time in renal graft recipients. *Wim P.D. Lemahieu, Bart D. Maes, Kirstin Verbeke, and Yves F.Ch. Vanrenterghem* 433

Predicting coronary heart disease in renal transplant recipients: A prospective study. *Didier Ducloux, Amir Kazory, and Jean-Marc Chalopin* 441

Ionic dialysance allows an adequate estimate of urea distribution volume in hemodialysis patients. *Salvatore Di Filippo, Celestina Manzoni, Simeone Andrulli, Giuseppe Pontoriero, Cesare Dell'Oro, Vincenzo La Milia, Flavia Tentori, Monica Crepaldi, Maria Carla Bigi, and Francesco Locatelli* 786

Effect of renal transplantation in childhood on longitudinal growth and adult height. *Richard Nissel, Ira Brázda, Reinhard Feneberg, Marianne Wigger, Christel Greiner, Uwe Querfeld, and Dieter Haffner* 792

Locking of tunneled hemodialysis catheters with gentamicin and heparin. *Christopher W. McIntyre, Lisa J. Hulme, Maarten Taal, and Richard J. Fluck* 801

Pulmonary calcification in hemodialysis patients: Correlation with pulmonary artery pressure values. *Mordechai Yigla, Zohar Keidar, Isra Safadi, Naveh Tov, Shimon A. Reisner, and Farid Nakhoul* 806

Myocardial scintigraphy using a fatty acid analogue detects coronary artery disease in hemodialysis patients. *Masato Nishimura, Tetsuya Hashimoto, Hiroyuki Kobayashi, Toyofumi Fukuda, Koji Okino, Noriyuki Yamamoto, Hiroshi Fujita, Naoto Inoue, Tsunehiko Nishimura, and Toshihiko Ono* 811

Protective effect of vitamin C on 8-hydroxy-2′-deoxyguanosine level in peripheral blood lymphocytes of chronic hemodialysis patients. *Der-Cherng Tarng, Tsung-Yun Liu, and Tung-Po Huang* 820

Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients. *Helga Frank, Karsten Heusser, Bernd Höffken, Peter Huber, Roland E. Schmieder, and Hans P. Schobel* 832

Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. *Makoto Anraku, Kenichiro Kitamura, Ayumi Shinohara, Masataka Adachi, Ayaka Suenaga, Toru Maruyama, Kei Miyanaka, Taku Miyoshi, Naoki Shiraishi, Hiroshi Nonoguchi, Masaki Otagiri, and Kimio Tomita* 841

Quantification of free water transport in peritoneal dialysis. *Watske Smit, Dirk G. Struijk, Marja M. Ho-dac-Pannekeet, and Raymond T. Krediet* 849

Hemodialysis-associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. *Tatsuya Shoji, Yoshiharu Tsubakihara, Masamitsu Fujii, and Enyu Imai* 1212

Dialysate magnesium level and blood pressure. *John Kyriazis, Konstantina Kalogeropoulou, Leonidas Bilirakis, Nikolaos Smirnioudis, Vasilios Pikounis, Dimitrios Stamatiadis, and Ekaterini Liolia* 1221

Clinical consequences of an individualized dialysate sodium prescription in hemodialysis patients. *Flavio M. de Paula, Aldo J. Peixoto, Luciano V. Pinto, David Dorigo, Pedro J. M. Patricio, and Sergio F.F. Santos* 1232

A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. *Braden Manns, Lesley Stevens, Dana Miskulin, William F. Owen, Jr., Wolfgang C. Winkelmayer, and Marcello Tonelli* 1239

Protective effects of FTY720 on chronic allograft nephropathy by reducing late lymphocytic infiltration. *Minghui Wang, Shanying Liu, Nengtai Ouyang, Erwei Song, Jens Lutz, and Uwe Heemann* 1248

Long-term exposure to new peritoneal dialysis solutions: Effects on the peritoneal membrane. *Siska Mortier, Dirk Faict, Casper G. Schalkwijk, Norbert H. Lameire, and An S. De Vriese* 1257

Vector length as a proxy for the adequacy of ultrafiltration in hemodialysis. *Luana Pillon, Antonio Piccoli, Edmund G. Lowrie, J. Michael Lazarus, and Glenn M. Chertow* 1266

Effectiveness and safety of dialysis vascular access procedures performed by interventional nephrologists. *Gerald A. Beathard, Terry Litchfield, and Physician Operators\Forum of RMS Lifeline, Inc.* .. 1622

Prognostic value of inducible myocardial ischemia in predicting cardiovascular events after renal transplantation. *Bertrand Dussol, Jean-Louis Bonnet, Jerome Sampol, Bernard Savin, Catherine De La Forte, Olivier Mundler, Gilbert Habib, Sophie Morange, Karine Barrau, Anderson Loundoun, Henri Vacher-Coponat, and Yvon Berland* 1633

Kinetic study of adenosine concentrations and the expression of adenosine deaminase in mononuclear cells during hemodialysis. *Bertrand Dussol, Emmanuel Fenouillet, Phillippe Brunet, Radj Purgus, Nicole Sauze, Louis Carrega, Laurence Mercier, Ibrahim Zouher, Guy Bechis, Yvon Berland, and Regis Guieu* 1640

Effect of spironolactone on K^+ homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients. *Luis Michea, Antonio Vukusich, Magdalena González, Carlos Zehnder, and Elisa T. Marusic* 1647

Patient and graft outcomes from older living kidney donors are similar to those from younger donors despite lower GFR. *Lourdes S. Peña de la Vega, Alvaro Torres, Humberto E. Bohorquez, Julie K. Heimbach, James M. Gloor, Thomas R. Schwab, Sandra J. Taler, Scott L. Nyberg, Michael B. Ishitani, Mikel Prieto, Jorge A. Velosa, Timothy S. Larson, Mark D. Stegall, Fernando G. Cosio, Stephen C. Textor, and Matthew D. Griffin* 1654

Interdialytic weight gain in patients on hemodialysis is associated with dry mouth and thirst. *Casper P. Bots, Henk S. Brand, Enno C.I. Veerman, Marianne Valentijn-Benz, Barbara M. Van Amerongen, Robert M. Valentijn, Pieter F. Vos, Joost A. Bijlsma, Pieter D. Bezemer, Piet M. ter Wee, and Arie V. Nieuw Amerongen* 1662

Kinetics of urea and β_2-microglobulin during and after short hemodialysis treatments. *John K. Leypoldt, Alfred K. Cheung, R. Barry Deeter, Alexander Goldfarb-Rumyantzev, Tom Greene, Thomas A. Depner, and John Kusek* 1669

TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. *Yoko Yoshio, Masanobu Miyazaki, Katsushige Abe, Tomoya Nishino, Akira Furusu, Yohei Mizuta, Takashi Harada, Yoshiyuki Ozono, Takehiko Koji, and Shigeru Kohno* 1677

Donor genomics influence graft events: The effect of donor polymorphisms on acute rejection and chronic allograft nephropathy. *Steven Hoffmann, Jenny Park, Lynn M. Jacobson, Rebecca J. Muehrer, David Lorentzen, David Kleiner, Yolanda T. Becker, Debra A. Hullett, Roslyn Mannon, Allan D. Kirk, and Bryan N. Becker* 1686

Analysis of the functional muscle-bone unit of the forearm in pediatric renal transplant recipients. *Eva-Maria Rüth, Lutz T. Weber, Eckhard Schoenau, Rainer Wunsch, Markus J. Seibel, Reinhard Feneberg, Otto Mehls, and Burkhard Tönshoff* 1694

Differentiation between chronic rejection and chronic cyclosporine toxicity by analysis of renal cortical mRNA. *Klaas Koop, Rene C. Bakker, Michael Eikmans, Hans J. Baelde, Emile de Heer, Leendert C. Paul, and Jan A. Bruijn* 2038

Screening for depression in hemodialysis patients: Associations with diagnosis, treatment, and outcomes in the DOPPS. *Antonio Alberto Lopes, Justin M. Albert, Eric W. Young, Sudtida Satayathum, Ronald L. Pisoni, Vittorio E. Andreucci, Donna L. Mapes, Nancy A. Mason, Shunichi Fukuhara, Björn Wikström, Akira Saito, and Friedrich K. Port* 2047

Uremic malnutrition is a predictor of death independent of inflammatory status. *Lara B. Pupim, Kayser Caglar, Raymond M. Hakim, Yu Shyr, and T. Alp Ikizler* 2054

Inhibition of neointimal hyperplasia in vascular grafts by sustained perivascular delivery of paclitaxel. *Takahisa Masaki, Ramesh Rathi, Gaylen Zentner, John K. Leypoldt, Syed F. Mohammad, Gregory L. Burns, Li Li, Sergey Zhuplatov, Thanit Chirananthavat, Seung-Jung Kim, Steven Kern, John Holman, Sung Wan Kim, and Alfred K. Cheung* 2061

Long-term follow-up study on bone mineral density and fractures after simultaneous pancreas-kidney transplantation. *Yves F.C. Smets, Johan W. de Fijter, Jan Ringers, Herman H.P.J. Lemkes, and Neveen A.T. Hamdy* 2070

Measurement of dialyzer clearance, dialysis time, and body size: Death risk relationships among patients. *Edmund G. Lowrie, Zhensheng Li, Norma Ofsthun, and J. Michael Lazarus* 2077

Ethnicity and survival on dialysis in west London. *Shilpanjali Prasad, Seema Singh, Neill Duncan, Tom D.H. Cairns, Megan Griffith, Nadey Hakim, Adam G. McLean, Andrew Palmer, Vassilios Papalois, and David Taube* 2416

Creatine supplementation does not decrease total plasma homocysteine in chronic hemodialysis patients. *Youri E.C. Taes, Joris R. Delanghe, Dirk De Bacquer, Michel Langlois, Lut Stevens, Inge Geerolf, Norbert H. Lameire, and An S. De Vriese* 2422

Relationship among catheter insertions, vascular access infections, and anemia management in hemodialysis patients. *Tricia L. Roberts, Gregorio T. Obrador, Wendy L. St. Peter, Brian J.G. Pereira, and Allan J. Collins* 2429

Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. *Simon J. Davies* 2437

A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. *Patrick T. Murray, Bharathi V. Reddy, Eric J. Grossman, Mary S. Hammes, Sharon Trevino, Janice Ferrell, Ignatius Tang, Marcie J. Hursting, Trisha R. Shamp, and Suzanne K. Swan* ... 2446

COMMENTARY

Plasma sodium and hypertension. *Hugh E. de Wardener, Feng J. He, and Graham A. MacGregor* 2454

TECHNICAL NOTE

Subclinical atherosclerosis is increased in type 2 diabetic patients with microalbuminuria evaluated by intima-media thickness and pulse wave velocity. *Hiroki Yokoyama, Tomomi Aoki, Masumi Imahori, and Masae Kuramitsu* 448

Global heterogeneity of glomerular volume distribution in early diabetic nephropathy. *Eiji Toyota, Yasuo Ogasawara, Katsukui Fujimoto, Tatsuya Kajita, Fumiyuki Shigeto, Takahisa Asano, Nozomi Watanabe, and Fumihiko Kajiya* 855

Free-breathing renal MR angiography with steady-state free-precession (SSFP) and slab-selective spin inversion: Initial results. *Marcus Katoh, Arno Buecker, Matthias Stuber, Rolf W. Günther, and Elmar Spuentrup* 1272

Enzyme replacement therapy administered during hemodialysis in patients with Fabry disease. *Markus Kosch, Hans-Georg Koch, Joao Paulo Oliveira, Carlos Soares, Francesco Bianco, Frank Breuning, Åse Krogh Rasmussen, and Roland M. Schaefer* 1279

EDITORIALS

Plasmin in renal interstitial fibrosis: Innocent or guilty? *Guoping Zheng and David C.H. Harris* 455

Parenteral iron therapy: Beyond anaphylaxis. *Muhammad G. Alam, Michelle W. Krause, and Sudhir V. Shah* 457

Do kidney tubules serve an angiogenic soup? *Adrian S. Woolf* 862

The quest for the gene responsible for medullary cystic kidney disease type 1. *Daniel G. Bichet and T. Mary Fujiwara* 864

Cyclic AMP, at the hub of the cystic cycle. *Vicente E. Torres* 1283

The flavors of vitamin D: Tasting the molecular mechanisms. *William G. Goodman* 1286

Renal transport proteins in excreted urine: Gold mine or gold dust? *Peter Gross* 1707

Promise for gene therapy in obstructive nephropathy. *Robert L. Chevalier* 1709

Albumin turns on a vicious spiral of oxidative stress in renal proximal tubules. *Enyu Imai, Hideaki Nakajima, and Jun-Ya Kaimori* 2085

Vascular calcification in ESRD: Another cloud appears in the perfect storm—but highlights a silver lining? *Dwight A. Towler* 2467

LETTERS TO THE EDITOR

Parathyroidectomy in ESRD. *Eric P. Cohen and John E. Moulder* 459

How can stenosis of one renal artery cause failure in two kidneys? *John Main* 460

Icodextrin-induced sterile peritonitis: Neutrophil activation and peritoneal injury. *Michel G. Tintillier* 460

7-84 PTH lowers bone turnover and explains why the 1-84 PTH/7-84 PTH ratio predicts bone turnover. *Thomas L. Cantor* 461

Are associational studies obfuscating? *Mae Thamer* 462

Challenges from bias when estimating change of renal allograft fuction. *Kevin C. Mange* 463

Development of malignancy after treatment of idiopathic membranous nephropathy. *Ming-Yu Lai, Wu-Chang Yang, and Chih-Ching Lin* 464

Plasma activin A in hemodialysis patients: Does brand of immunoassay matter? *Jacek Borawski, Beata Naumnik, and Michal Mysliwiec* 465

Effect of obesity on PD versus HD survival: Is caloric intake the discriminating factor? *Shariq Ahmad and Abdulla K. Salahudeen* 866

On the epithelial-mesenchymal transition of mesothelial cells. *Rafael Selgas, José Jiménez-Heffernan, and Manuel López-Cabrera* 866

A catalog of gene expressioni in the developing kidney. *François Jouret, Huguette Debaix, and Olivier Devuyst* 867

Urea space and body water. *Edmund G. Lowrie* 868

Is C0 better than C2 as a determinant of rejection in renal transplant recipients? *Karsten Midtvedt* .. 869

About the mechanisms of renoprotective effect of angiotensin inhibitors on lupus nephritis. *Guillermo Pérez de Lema, Francisco Mampaso, and Detlet Schlöndorff* 869

Therapy of Fabry disease. *Julia Kleinert, Anna-Christine Hausser, Matthias Lorenz, Manuela Födinger, and Gere Sunder-Plassmann* 1288

The search for maturity... . *Luc Turmel-Rodrigues* 1289

Differential diagnosis between X-linked Alport syndrome and thin basement membrane nephropathy. *Gianfranco Rizzoni and Laura Massella* 1289

Diagnosis of Alport syndrome. *Clifford E. Kashtan* 1290

Dialysis dose and gender: A different hypothesis. *Edmund G. Lowrie, Norma Ofsthun, and Zhengsheng Li* 1291

Prevention of acute renal failure with N-acetylcysteine—Enough is enough? *Hendrik Koller and Alexander R. Rosenkranz* 1292

Underuse of Hardy-Weinberg equilibrium. *Gere Sunder-Plassmann and Manuela Födinger.* 1711

Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: A meta-analysis. *Marcello Tonelli, William F. Owen, Jr., Kailash Jindal, Wolfgang C. Winkelmayer, and Braden Manns* 1712

Mycophenolate mofetil in IgA nephropathy... *Vincenzo Sepe, Natalia Rossi, Gabriella Adamo, and Antonio Dal Canton* 1713

Hepatic iron in hemodialysis patients. *Steven Fishbane, Nobuyuki Miyawaki, and Naveed Masani* ... 1714

The impact of serum uric acid on cardiovascular outcomes in the LIFE study. *Stella S. Daskalopoulou, Vasilios G. Athyrois, Moses Elisaf, and Dmitri P. Mikhailidis* 1715

Heterozygous NPHS1 or NPHS2 mutations in responsive nephrotic syndrome and the multifactorial origin of proteinuria. *Gianluca Caridi, Robetra Bertelli, Francesco Perfumo, and Gian Marco Ghiggeri* 1715

Different meanings of "glomerular tip lesion." *Alexander James Howie and Dwomoa Adu* 1716

How can we be sure that renal dysfunction after coronary angiography is just explained by contrast nephropathy? *Caterina Canavese, Fabio Morra, Veronica Morellini, Elisa Lazzarich, Maddalena Brustia, Mario Bo, and Piero Stratta* 1717

Phosphate intake and the CARE study. *Denis Fouque* 2088

Using the right MDRD equation. *Vincent Launay-Vacher, Hassane Izzedine, and Gilbert Deray* 2089

Pathophysiology of ANCA-associated vasculitis: Are ANCA really pathogenic? A note of caution. *Gertrud Maria Hänsch and Konrad Andrassy* 2090

Bioimpedance vector migration up to three days after the hemodialysis session. *Antonio Piccoli and Marta Codognotto* 2091

End-stage renal disease increases plasma transcobalamin and neutralizes influence of TCN 776C>G polymorphism. *Wafa Anwar, Philippe Gérard, Abderahim Moutabarrek, Farès Namour, and Jean-Louis Guéant* 2092

Microinflammation versus inflammation in chronic renal failure patients. *George Tsirpanlis, Stylianos Chatzipanagiotou, and Nicolaou Chrysoula* 2093

Additional antiretroviral and immunosuppressive drug-drug interactions. *Anthony J. Busti* 2469

The influence of plasma volume on blood pressure in regular hemodialysis patients. *Salwa Ibrahim, Dawlat Belal, and Ahmed Al-Taweel* 2470

NEPHROLOGY FORUM

Restructuring the ESRD payment system in the United States. *Allen R. Nissenson* 466

Actin cytoskeleton in ischemic acute renal failure. *Bruce A. Molitoris* 871

The changing face of childhood nephrotic syndrome. *Russell Chesney* 1294

Atherosclerosis and uremic retention solutes. *Walter H. Hörl* 1719

Diabetic nephropathy: Linking histology, cell biology, and genetics. *Sharon Adler* 2095

The changing face of schistosomal glomerulopathy. *Rashad Barsoum* 2472

INTERNATIONAL SOCIETY OF NEPHROLOGY

Membership 477, 884, 1303, 1732, 2107, 2485

Meeting Announcements 477, 884, 1303, 1732, 2107, 2485

Awards & Grants 885, 1732

Books Received 885, 1304

Errata 886, 1304, 1733, 2108, 2486

FOREFRONTS IN NEPHROLOGY EVOLVING BASIC CONCEPTS IN ISCHEMIC INJURY

Evolving basic concepts in ischemic injury. *Marc E. De Broe, Joseph V. Bonventre, Bruce A. Molitoris, and Hermann Haller* 479

Ischemic acute renal failure: An inflammatory disease? *Joseph V. Bonventre and Anna Zuk* 480

Inflammatory cells in ischemic acute renal failure. *John J. Friedewald and Hamid Rabb* 486

T cells as mediators in renal ischemia/reperfusion injury. *Dirk K. Ysebaert, Kathleen E. De Greef, Annelies De Beuf, An R. Van Rompay, Sven Vercauteren, Veerle P. Persy, and Marc E. De Broe* 491

Endothelial injury and dysfunction: Role in the extension phase of acute renal failure. *Bruce A. Molitoris and Timothy A. Sutton* 496

Apoptotic pathways in ischemic acute renal failure. *Gur P. Kaushal, Alexei G. Basnakian, and Sudhir V. Shah* 500

Apoptosis in ischemic renal injury: Roles of GTP depletion and p53. *Pierre C. Dagher* 506

Cell cycle regulation: Repair and regeneration in acute renal failure. *Peter M. Price, Judit Megyesi, and Robert L. Safirstein* 509

The role of mitochondria in ischemia/reperfusion injury in organ transplantation. *Wayel Jassem and Nigel D. Heaton* 514

Progenitor cells in the kidney: Biology and therapeutic perspectives. *Maarten B. Rookmaaker, M.C. Verhaar, A.J. van Zonneveld, and Ton J. Rabelink* 518

Long-term effects of acute ischemia and reperfusion injury. *Faikah Gueler, Winfried Gwinner, Anke Schwarz, and Hermann Haller* 523

Regulation of intestinal epithelial gene expression in hypoxia. *Cormac T. Taylor* 528

SATELLITE SYMPOSIUM RENAL BIOPSY REGISTRIES

Introduction *F. Paolo Schena and Loreto Gesualdo* 889

The Italian experience of the national registry of renal biopsies. *Loreto Gesualdo, Anna Maria Di Palma, Luigi Francesco Morrone, Giovanni Fabrizio Strippoli, and Francesco Paolo Schena, on behalf of the Italian Immunopathology Group, Italian Society of Nephrology* 890

The Danish Renal Biopsy Register. *James Heaf* 895

Clinicopathologic correlations of renal pathology in Spain. *Francisco Rivera, Juan Manuel López-Gómez, Rafael Pérez-García, on behalf of the Spanish Registry of Glomerulonephritis* 898

Epidemiologic data of primary glomerular diseases in western France. *Pierre Simon, Marie-Paule Ramee, Rehouni Boulahrouz, Corina Stanescu, Christophe Charasse, Kim Seng Ang, Françoise Leonetti, Gérard Cam, Eric Laruelle, Valérie Autuly, and Nathalie Rioux* 905

Signs and symptoms of thin basement membrane nephropathy: A prospective regional study on primary glomerular disease—The Limburg Renal Registry. *Pieter van Paassen, Peter J.C. van Breda Vriesman, Henk van Rie, and Jan Willem Cohen Tervaert* 909

Outcome study of renal biopsy patients in Okinawa, Japan. *Kunitoshi Iseki, Fujihiko Miyasato, Hajime Uehara, Kiyoyuki Tokuyama, Shigeki Toma, Keizo Nishime, Shinichiro Yoshi, Yoshiki Shiohira, Takashi Oura, Masahiko Tozawa, and Koshiro Fukiyama* 914

Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies. *Lei-Shi Li and Zhi-Hong Liu* 920

ACKNOWLEDGMENT OF REVIEWERS 2487

AUTHOR INDEX 2493

VOLUME 66 ACCUMULATED TABLE OF CONTENTS 2516

KIDNEY INTERNATIONAL

Volume 66, Supplement 89, July 2004

Mechanisms Determining the Ratio of Conductivity

Clearance to Urea Clearance

Table of contents

Introduction. *Francesco Locatelli* S-1

Mechanisms determining the ratio of conductivity clearance to urea clearance. *Frank A. Gotch, Froilan M. Panlilio, Rosemary A. Buyaki, Erjun X. Wang, Thomas I. Folden, and Nathan W. Levin* S-3

Volume 66, Supplement 90, September 2004

Hyperphosphatemia and Cardiovascular Calcification

in Patients with End-Stage Renal Failure

Table of contents

Introduction. *Wajeh Y. Qunibi* S-1

Projecting the United States ESRD population: Issues regarding treatment of patients with ESRD. *Lynda Anne Szczech and Ira L. Lazar* S-3

Consequences of hyperphosphatemia in patients with end-stage renal disease (ESRD). *Wajeh Y. Qunibi* S-8

The role of abnormal phosphorus metabolism in the progression of chronic kidney disease and metastatic calcification. *Allen C. Alfrey* S-13

Cardiovascular calcification in patients with chronic renal failure: Are we on target with this risk factor? *Peter A. McCullough and Sandeep Soman* S-18

A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. *Michael Emmett* S-25

Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: Results of the CARE study. *Wajeh Y. Qunibi and Charles R. Nolan* S-33

Acid loading during treatment with sevelamer hydrochloride: Mechanisms and clinical implications. *Barton Brezina, Wajeh Y. Qunibi, and Charles R. Nolan* S-39

The impact of calcimimetic agents on the use of different classes of phosphate binders: Results of recent clinical trials. *Lynda Anne Szczech* S-46

KIDNEY INTERNATIONAL

Volume 66, Supplement 91, October 2004

A Festschrift in Honor of Thomas E. Andreoli

Table of contents

A note from the editor. *Saulo Klahr* S-1

Preface. *Donald W. Seldin* S-2

Acknowledgments. *Robert Safirstein* S-4

Novel aspects in regulated expression of the renal type IIa Na/P_i-cotransporter. *Desa Bacic, Carsten A. Wagner, Nati Hernando, Brigitte Kaissling, Jürg Biber, and Heini Murer* S-5

PTH revisited. *Peter A. Friedman* S-13

Renal water reabsorption: A physiologic retrospective in a molecular era. *James A. Schafer* S-20

Calcium and salinity sensing by the thick ascending limb: A journey from mammals to fish and back again. *Steven C. Hebert* S-28

Romancing the macula densa at UAB. *L. Gabriel Navar and P. Darwin Bell* S-34

Kinase-mediated transcription, activators of nongenotropic estrogen–like signaling (ANGELS), and osteoporosis: A different perspective on the HRT dilemma. *Stavros C. Manolagas, Stavroula Kousteni, Jin-Ran Chen, Maria Schuller, Lilian Plotkin, and Teresita Bellido* S-41

Oxidants and iron in chronic kidney disease. *Sudhir V. Shah* S-50

Inflammatory cytokines in acute renal failure. *Ganesan Ramesh and W. Brian Reeves* S-56

Acute renal failure: From renal physiology to the renal transcriptome. *Robert L. Safirstein* S-62

KIDNEY INTERNATIONAL

Volume 66, Supplement 92, November 2004

Albuminuria: Risk Marker and Target for Treatment

Table of contents

Introduction. *Dick de Zeeuw, George Bakris, and Marc A. Pfeffer* S-1

Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? *Dick de Zeeuw* S-2

OVERVIEW

Trends in the incidence of treated end-stage renal failure in The Netherlands: Hope for the future? *Ron T. Gansevoort, Bart van der Heij, Coen A. Stegeman, Frank T. de Charro, Martin G. Nieuwenhuizen, Dick de Zeeuw, and Paul E. de Jong* S-7

Cardiovascular risk in chronic kidney disease. *Nagesh S. Anavekar and Marc A. Pfeffer* S-11

Which albumin should we measure? *Gavin J. Becker* S-16

ALBUMINURIA PREDICTING OUTCOME IN THE GENERAL POPULATION

An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. *Jacobien C. Verhave, Ron T. Gansevoort, Hans L. Hillege, Stephan J.L. Bakker, Dick De Zeeuw, and Paul E. de Jong, for the PREVEND Study Group* S-18

Prevalence of albuminuria in Australia: The AusDiab Kidney Study. *Robert C. Atkins, Kevan R. Polkinghorne, Esther M. Briganti, Jonathan E. Shaw, Paul Z. Zimmet, and Steven J. Chadban* S-22

Albuminuria: Marker or target in indigenous populations. *Wendy Hoy and Stephen P. McDonald* S-25

Demographic and epidemiologic transition in the developing world: Role of albuminuria in the early diagnosis and prevention of renal and cardiovascular disease. *Ricardo Correa-Rotter, Sarala Naicker, Ivor J. Katz, Sanjay K. Agarwal, Raul Herrera Valdes, Dan Kaseje, Bernardo Rodriguez-Iturbe, Faissal Shaheen, and Chitr Sitthi-Amorn, on behalf of the ISN-COMGAN Bellagio Study Group 2004* S-32

ALBUMINURIA PREDICTING OUTCOME IN DIABETES

Albuminuria predicting outcome in diabetes: Incidence of microalbuminuria in Asia–Pacific Rim. *Matthew R. Weir* S-38

Microalbuminuria, glycemic control, and blood pressure predicting outcome in diabetes type 1 and type 2. *Carl Erik Mogensen and Per Logstrup Poulsen* S-40

Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: Further evidence for a link between microalbuminuria and endothelial dysfunction—The Hoorn Study. *Coen D.A. Stehouwer, Ronald M.A. Henry, Jacqueline M. Dekker, Giel Nijpels, Robert J. Heine, and Lex M. Bouter* S-42

ALBUMINURIA PREDICTING OUTCOME IN HEART DISEASE

Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. *Julian Segura, Carlos Campo, and Luis M. Ruilope* S-45

Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: A case for albuminuria. *Nagesh S. Anavekar, Daniel J. Gans, Tomas Berl, Richard D. Rohde, William Cooper,*

Amitabha Bhaumik, Lawrence G. Hunsicker, Jean-Lucien Rouleau, Julia B. Lewis, Clive Rosendorff, Jerome G. Porush, Paul L. Drury, Enric Esmatjes, Itamar Raz, Phillippe Vanhille, Franceso Locatelli, Samuel Goldhaber, Edmund J. Lewis, and Marc A. Pfeffer S-50

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study. *Hans Ibsen, Kristian Wachtell, Michael H. Olsen, Knut Borch-Johnsen, Lars H. Lindholm, Carl Erik Mogensen, and Björn Dahlöf* S-56

Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. *Johannes F.E. Mann, Qi-Long Yi, and Hertzel C. Gerstein* S-59

MECHANISM AND MEASUREMENT OF ALBUMINURIA

Glomerular filtration of albumin: How small is the sieving coefficient? *William M. Deen and Matthew J. Lazzara* S-63

Albumin-like material in urine. *Wayne D. Comper and Tanya M. Osicka* S-65

Mechanism of albuminuria associated with cardiovascular disease and kidney disease. *Leileata M. Russo, Wayne D. Comper, and Tanya M. Osicka* S-67

Which method for quantifying urinary albumin excretion gives what outcome? A comparison of immunonephelometry with HPLC. *Jacoline W. Brinkman, Stephan J.L. Bakker, Ron T. Gansevoort, Hans L. Hillege, Ido P. Kema, Reinold O.B. Gans, Paul E. de Jong, and Dick de Zeeuw* S-69

Why is proteinuria an ominous biomarker of progressive kidney disease? *Kambiz Zandi-Nejad, Allison A. Eddy, Richard J. Glassock, and Barry M. Brenner* S-76

ALBUMINURIA PREDICTING OUTCOME IN RENAL DISEASE

Proteinuria predicting outcome in renal disease: Nondiabetic nephropathies (REIN). *Giuseppe Remuzzi, Carlos Chiurchiu, and Piero Ruggenenti* S-90

Detecting and managing patients with type 2 diabetic kidney disease: Proteinuria and cardiovascular disease. *William E. Mitch, Shahnaz Shahinfar, Tania Z. Dickson, Dick de Zeeuw, and Zhongxin Zhang* S-97

Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. *Lawrence G. Hunsicker, Robert C. Atkins, Julia B. Lewis, Gregory Braden, Paul J. Champion de Crespigny, Giacomo DeFerrari, Paul Drury, Francesco Locatelli, Thomas B. Wiegmann, and Edmund J. Lewis, for the Collaborative Study Group* S-99

Proteinuria and hypertensive nephrosclerosis in African Americans. *Robert D. Toto* S-102

ALBUMINURIA AS A THERAPY TARGET FOR RENAL-CV PROTECTION

The effects of valsartan on the accumulation of circulating and renal advanced glycation end products in experimental diabetes. *Josephine M. Forbes, Merlin C. Thomas, Suzanne R. Thorpe, Nathan L. Alderson, and Mark E. Cooper* S-105

Beneficial impact on cardiovascular risk factors by dual blockade of the renin-angiotensin system in diabetic nephropathy. *Peter Jacobsen and Hans-Henrik Parving* S-108

Framingham score and microalbuminuria: Combined future targets for primary prevention? *Folkert W. Asselbergs, Hans L. Hillege, and Wiek H. van Gilst* S-111

Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy. *Charles M. Alexander, Paulette A. Lyle, William F. Keane, George W. Carides, Zhongxin Zhang, and Shahnaz Shahinfar* S-115

Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria. *Andrew J. Palmer and Roger A. Rodby* S-118

INCLUSION OF ALBUMIN AS A TARGET IN THERAPY GUIDELINES

Inclusion of albumin as a target in therapy guidelines: Guidelines for chronic kidney disease. *David G. Warnock* S-121

Inclusion of albuminuria in hypertension and heart guidelines. *George Bakris* S-124

Albuminuria as a surrogate marker for drug development: A European Regulatory perspective. *Gonzalo Calvo and Fernando de Andres-Trelles* S-126